McKesson Corporation reported strong fiscal fourth-quarter results, highlighting an 18% increase in adjusted earnings per diluted share to $39.11 for the year and a projected rise to between $43.80 and $44.60 for fiscal 2027. Consolidated revenues reached $403 billion, driven by robust performance in specialty pharmaceuticals and oncology, with notable contributions from GLP-1 drug distribution, which generated $14 billion in quarterly revenue—up 22% year-over-year.

The company’s strategic focus on capital deployment is evident, with $5.1 billion returned to shareholders through share repurchases and dividends. McKesson is also progressing with the separation of its Medical-Surgical Solutions segment, which is expected to unlock additional shareholder value. The company’s operating efficiency improved significantly, aided by automation and AI, positioning it well for future growth.

For market professionals, McKesson’s solid earnings guidance and ongoing capital return strategy signal a commitment to shareholder value, making it a stock to watch as it continues to optimize its portfolio and enhance operational performance.

Source: fool.com